ARCUTIS BIOTHERAPEUTICS, INC. Amortization of Debt Issuance Costs and Discounts
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Amortization of Debt Issuance Costs and Discounts of $1.59 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2022-11-08
- ARCUTIS BIOTHERAPEUTICS, INC. amortization of debt issuance costs and discounts for the quarter ending 2022-09-30 was $802.00K.
- ARCUTIS BIOTHERAPEUTICS, INC. amortization of debt issuance costs and discounts for the quarter ending 2022-06-30 was $396.00K.
- ARCUTIS BIOTHERAPEUTICS, INC. amortization of debt issuance costs and discounts for the quarter ending 2022-03-31 was $392.00K.
- ARCUTIS BIOTHERAPEUTICS, INC. amortization of debt issuance costs and discounts for the quarter ending 2021-09-30 was $0.00.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month |
|---|---|---|---|
| 2022-09-30 | $802.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.20M derived: sum of 2 quarters · filed 2022-11-08 | $1.59M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $396.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $788.00K 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $392.00K 10-Q · filed 2022-05-05 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |